JP2020505465A5 - - Google Patents

Download PDF

Info

Publication number
JP2020505465A5
JP2020505465A5 JP2019560493A JP2019560493A JP2020505465A5 JP 2020505465 A5 JP2020505465 A5 JP 2020505465A5 JP 2019560493 A JP2019560493 A JP 2019560493A JP 2019560493 A JP2019560493 A JP 2019560493A JP 2020505465 A5 JP2020505465 A5 JP 2020505465A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
chain variable
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019560493A
Other languages
English (en)
Japanese (ja)
Other versions
JP7140403B2 (ja
JP2020505465A (ja
Filing date
Publication date
Priority claimed from GBGB1701194.1A external-priority patent/GB201701194D0/en
Application filed filed Critical
Publication of JP2020505465A publication Critical patent/JP2020505465A/ja
Publication of JP2020505465A5 publication Critical patent/JP2020505465A5/ja
Application granted granted Critical
Publication of JP7140403B2 publication Critical patent/JP7140403B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019560493A 2017-01-24 2018-01-24 Lightに結合する抗原結合分子 Active JP7140403B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1701194.1A GB201701194D0 (en) 2017-01-24 2017-01-24 Antigen binding molecules that bind light
GB1701194.1 2017-01-24
PCT/GB2018/050203 WO2018138496A1 (en) 2017-01-24 2018-01-24 Antigen binding molecules that bind light

Publications (3)

Publication Number Publication Date
JP2020505465A JP2020505465A (ja) 2020-02-20
JP2020505465A5 true JP2020505465A5 (enExample) 2021-03-11
JP7140403B2 JP7140403B2 (ja) 2022-09-21

Family

ID=58463068

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019560493A Active JP7140403B2 (ja) 2017-01-24 2018-01-24 Lightに結合する抗原結合分子

Country Status (7)

Country Link
US (2) US11827673B2 (enExample)
EP (1) EP3574014A1 (enExample)
JP (1) JP7140403B2 (enExample)
KR (1) KR20190110578A (enExample)
CN (1) CN110461875B (enExample)
GB (2) GB201701194D0 (enExample)
WO (1) WO2018138496A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114516913B (zh) * 2020-11-19 2023-04-28 东莞市朋志生物科技有限公司 抗n末端脑钠肽前体的抗体和检测试剂盒
CN116355860A (zh) * 2021-12-28 2023-06-30 四川远大蜀阳药业有限责任公司 分泌抗h因子抗体的杂交瘤细胞株、抗h因子抗体及其应用
WO2025195445A1 (zh) * 2024-03-21 2025-09-25 北京三诺佳邑生物技术有限责任公司 特异性结合light和tslp的多特异性抗体以及组合物及其应用
KR20250151071A (ko) 2024-04-13 2025-10-21 백수경 이동식 방제 박스
US20260062472A1 (en) * 2024-08-28 2026-03-05 Earendil Labs Inc. Bispecific antibody and use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3734795A (en) 1971-04-23 1973-05-22 Lindsay Wire Weaving Co Patch and seam for plastic belts
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
EP0985033A4 (en) 1997-04-04 2005-07-13 Biosite Inc POLYVALENT AND POLYCLONAL LIBRARIES
US6998108B1 (en) 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6140467A (en) 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
DK1674575T3 (da) 2000-04-12 2010-11-29 Jolla Inst Allergy Immunolog Ligand for Herpes simplex-indgangsmediator og fremgangsmåder til anvendelse
EP1336619A3 (en) 2002-02-19 2003-12-10 Millenium Pharmaceuticals, Inc. Combination of a HVEM-LIGHT inhibitor and an immunosuppressive agent in the treatment or prevention of immune disorders
WO2003089575A2 (en) * 2002-04-15 2003-10-30 Human Genome Sciences, Inc. Antibodies that specifically bind to tl5
SI2292663T1 (sl) * 2006-08-28 2014-02-28 Kyowa Hakko Kirin Co., Ltd Antagonistična humana monoklonska protitelesa, specifična za humani LIGHT
EA021255B1 (ru) 2006-08-28 2015-05-29 Киова Хакко Кирин Ко., Лимитед Антагонистические моноклональные антитела человека, специфичные в отношении light человека
US8440185B2 (en) 2006-12-26 2013-05-14 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders
JP6071165B2 (ja) 2007-05-31 2017-02-01 ゲンマブ エー/エス 安定なIgG4抗体
EP3750554A3 (en) 2007-09-18 2021-07-28 La Jolla Institute for Allergy and Immunology Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment
AU2009308707A1 (en) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. LIGHT targeting molecules and uses thereof
WO2010111180A1 (en) * 2009-03-24 2010-09-30 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against light and uses thereof
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
EP4527855A3 (en) 2012-03-26 2025-06-11 Sanofi Stable igg4 based binding agent formulations
WO2013148350A2 (en) * 2012-03-26 2013-10-03 Sanofi Anti-light antibody therapy for inflammatory bowel disease
PL3041831T3 (pl) 2013-09-06 2021-07-19 Research Development Foundation Postacie soli alfa-TEA: kompozycje i zastosowania do leczenia choroby
TWI617309B (zh) 2013-10-25 2018-03-11 製藥公司 使用布魯頓氏酪胺酸激酶抑制劑之治療及免疫療法
WO2015107331A2 (en) * 2014-01-14 2015-07-23 Kymab Limited Anti-light antibodies
US20170165230A1 (en) 2014-04-09 2017-06-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
US20180016345A1 (en) 2015-02-05 2018-01-18 La Jolla Institute For Allergy And Immunology Light inhibitors for scleroderma and skin fibrotic disease treatment
CA2994719A1 (en) 2015-08-21 2017-03-02 The Children's Hospital Of Philadelphia Methods of treating autoimmune conditions in patients with genetic variations in dcr3 or in a dcr3 network gene
US11312781B2 (en) * 2018-01-24 2022-04-26 Capella Bioscience Ltd. Antigen binding molecules that bind LIGHT

Similar Documents

Publication Publication Date Title
CN109195993B (zh) 串联fab免疫球蛋白及其用途
JP2020513791A5 (enExample)
AU2015322141B2 (en) High affinity and aggregatively stable antibodies on the basis of variable domains Vl and a derivative VHH
JP2014534218A5 (enExample)
JP2012501670A5 (enExample)
TW201833141A (zh) 抗b7-h3抗體、其抗原結合片段及其醫藥用途
HRP20191219T1 (hr) Molekule protutijela koje imaju specifičnost za ljudski ox40
JP2012524071A5 (enExample)
HRP20170041T1 (hr) Anti-c5a vezujuće grupe s visokom blokirajućom aktivnošću
JP2011509245A5 (enExample)
JP2010526028A5 (enExample)
JP2014500009A5 (enExample)
CA2896548A1 (en) Multivalent binding protein compositions
CN114144431B (zh) 人源化抗TNFα抗体及其用途
EP4267615A1 (en) Antibody variable domains that bind il-4r
JP2025500971A5 (enExample)
JP2011207882A5 (enExample)
JP2012531922A5 (ja) Toll様受容体2へのヒト化抗体またはその抗原結合部位
JP2014519334A5 (enExample)
JP2015537190A5 (enExample)
JP2016520595A5 (enExample)
JP2024532495A (ja) 抗ヒトtslpモノクローナル抗体及びその使用
WO2015191934A2 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
JP2012514458A5 (enExample)
RU2014114015A (ru) Способы лечения воспалительных расстройств с использованием антител против m-csf